Perfluoroalkyl Chain-Modified Artificial Viral Capsid for Enhanced Intracellular Delivery of mRNA (2025)
Sequence: INHVGGTGGAIMAPVAVTRQLVGS + CADC6F13F (C-terminal conjugation)
| Experiment Id | EXP000763 |
|---|---|
| Paper | Perfluoroalkyl Chain-Modified Artificial Viral Capsid for Enhanced Intracellular Delivery of mRNA |
| Peptide | β-annulus-PFA |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | β-annulus-PFA 10 μM; β-annulus 12.8 μM; dT20-SS-β-annulus 2.2 μM (assembly) |
| Rna Concentration | 0.44 μM mRNA |
| Mixing Ratio | PFA content 40% (optimized) |
| Formulation Format | Artificial viral capsid (self-assembled peptide nanocapsid) |
| Formulation Components | Co-assembly of β-annulus-PFA, dT20-SS-β-annulus, and β-annulus |
| Size Nm | 150.00 |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HepG2; HeLa; HEK293T |
| Animal Model | |
| Administration Route | Cell incubation |
| Output Type | mRNA delivery and protein expression |
| Output Value | Robust mCherry expression; higher than lipofectamine |
| Output Units | |
| Output Notes | Only the full PFA-modified capsid shows efficient uptake and translation; individual components are nonfunctional alone |
| Toxicity Notes | Minimal cytotoxicity (>90% viability) |
| Curation Notes |